| Ytd | -62.85% | |
| 1y | -52.00% |
| Open | 1.58 | Prev Close | 1.60 | Low | 1.02 | High | 1.60 | Mkt Cap | 3.05M |
| Vol | 32.77M | Avg Vol | 248.88K | EPS | -1.75 | P/E | N/A | Forward P/E | -3.25 |
| Beta | -0.50 | Short Ratio | 10.12 | Inst. Own | 12.08% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-14 | 50-d Avg | 1.83 | 200-d Avg | 2.62 | 1yr Est | 1.75 |
TCRT News
Gainers DataMEDS AI (NASDAQ:MEDS) shares increased by 12.9% to $4.24 during Friday's after-mark
Gainers IM Cannabis (NASDAQ:IMCC) stock increased by 246.0% to $6.02 during Friday's regular se
The offering is expected to close on or about September 21, 2026, subject to the satisfaction of cus
Alaunos Therapeutics announces pricing of a public offering of common stock and pre-funded warrants
Gainers IM Cannabis (NASDAQ:IMCC) stock rose 108.5% to $3.63 during Friday's pre-market session
TCRT: 69% | Alaunos Therapeutics On Thursday Filed Patent Application "Identification Of Neoanti
https://ppubs.uspto.gov/api/pdf/downloadPdf/US-20260273054-A1?source=US-PGPUB&requestToken=eyJzd
Shares of Alaunos Therapeutics Inc (NASDAQ:TCRT) rose sharply in pre-market trading following a Secu
Alaunos rose 21.8% after adopting amended bylaws; Cheetah Net led gainers, while Xenon dropped 27.6%
Alaunos Therapeutics shares surged 29% in after-hours trading Thursday after the company adopted new
Gainers Alaunos Therapeutics (NASDAQ:TCRT) shares moved upwards by 30.0% to $2.08 during Thursday&#
Gainers Basel Medical Group (NASDAQ:BMGL) stock moved upwards by 14.1% to $4.68 during Wednesday
Gainers DataMEDS AI (NASDAQ:MEDS) shares rose 124.1% to $3.63 during Wednesday's pre-market ses
Gainers VolitionRX (AMEX:VNRX) shares increased by 102.2% to $0.69 during Thursday's pre-market
This statistical finding supports a lower liver-weight signal after adjustment for body fat percenta
Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 159.6% to $7.68 during Monday&
ALN1003 demonstrated consistent, favorable effects across key drivers of metabolic disease, includin
ALN1003 demonstrated consistent, favorable effects across key drivers of metabolic disease, includin
Alaunos Therapeutics, Inc. (NASDAQ:TCRT) today announced updated preclinical data from non-GLP diet-
FORT LAUDERDALE, Fla., May 18, 2026 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (Nasdaq: TCRT) to
Seasoned Biopharmaceutical Attorney with Deep IP, Clinical-Stage, and Nasdaq Public Company Experien
Alaunos Therapeutics Inc. (NASDAQ: TCRT) shares are down on Monday after the company announced precl
The lead drug candidate, ALN1003, showed dose-related body weight loss and favorable body compositio
Alaunos' ALN1003 shows dose dependent weight loss, better body composition, reduced liver weight, an
Alaunos Therapeutics, Inc. (NASDAQ: TCRT - Get Free Report) saw a significant decline in short inter
Alaunos Therapeutics, Inc. (NASDAQ: TCRT - Get Free Report) was up 3.1% during mid-day trading on We
Healthcare and biotech stocks have lagged broader markets this year, but a growing number of names h
Several biotech stocks have seen their strength fade over the past week, with their Momentum scores
Alaunos Therapeutics (NASDAQ:TCRT) reported quarterly losses of $(0.63) per share. This is a 11.27 p
HOUSTON, June 23, 2025 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (Nasdaq: TCRT) (the “Company”)
PMGC Capital LLC ("PMGC Capital"), a wholly owned subsidiary of PMGC Holdings Inc. (NASDAQ:E
NEWPORT BEACH, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- PMGC Capital LLC (“PMGC Capital”), a wholly
NEWPORT BEACH, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- PMGC Capital LLC (“PMGC Capital,” “we,” “our